$バイオデクサ・ファーマシューティカルズ(BDRX.US)$ NEWS (late) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting Biodexa Pharmaceuticals PLC, through its licensor Emtora Biosciences, will present the Phase 2 clinical trial results of eRapa in Familial Adenomatous Polyposis at the 2024 Digestive Disease Week Annual Meeting. The presentation is set for May 18-21, 2024, in Washin...
$バイオデクサ・ファーマシューティカルズ(BDRX.US)$ pleased to announce that's its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024.
$バイオデクサ・ファーマシューティカルズ(BDRX.US)$accidentally bought 2700 shares phuhk hope it pumps monday, n e one know what time this stock opens pre market, i know pre is at 4 but this stock usually seems to open at different times on pre
バイオデクサ・ファーマシューティカルズに関するコメント
They just might let this one go.... in one month after they beat it down again.
NEWS (late)
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
Biodexa Pharmaceuticals PLC, through its licensor Emtora Biosciences, will present the Phase 2 clinical trial results of eRapa in Familial Adenomatous Polyposis at the 2024 Digestive Disease Week Annual Meeting. The presentation is set for May 18-21, 2024, in Washin...
pleased to announce that's its licensor Emtora Biosciences has announced that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") are to be presented at the prestigious 2024 Digestive Disease Week annual meeting in Washington DC on May 18-21, 2024.
News
まだコメントはありません